Loading market movers...

PRGN-2009 plus Pembrolizumab

Phase 2

Precigen, Inc. (PGEN)

00%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

PGENPhase 2$2.7B

PRGN-2009 plus Pembrolizumab Phase 2 Est. Readout

PRGN-2009 plus Pembrolizumab• Cervical Cancer24

Nov 2026~Estimated

00%

Competitive Landscape

0 competitors in Cervical Cancer

View Full Landscape

Drug Information

Target Indication

Cervical Cancer

Clinical Trial

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

PGEN

Precigen, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

PRGN-2012 - Phase I; Dose Level 1Phase 2

Recurrent Respiratory Papillomatosis

AG019 - Low DosePhase 2

Diabetes type1

PRGN-2012 - Phase I; Dose Level 2Phase 2

Recurrent Respiratory Papillomatosis

PRGN-2012 - Phase II; Dose Level 2Phase 2

Recurrent Respiratory Papillomatosis

AG019 - High DosePhase 2

Diabetes type1

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts